Jevtana cabazitaxel regulatory update

Sanofi disclosed in its 2Q14 earnings that Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved Jevtana cabazitaxel to treat prostate cancer. The taxane derivative is approved in the U.S...